Tag: Tricyclic antidepressant (secondary amine)

  • Nortriptyline

    Tricyclic antidepressant (secondary amine)

    The N-desmethyl active metabolite of amitriptyline; a NET-preferring TCA with a more favorable side effect profile.

    Abstract

    Nortriptyline (3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methylpropan-1-amine; CAS 72-69-5; molecular formula C19H21N; molecular weight 263.38) is the N-desmethyl active metabolite of amitriptyline, marketed independently as Pamelor and Aventyl after FDA approval in 1964. As a secondary amine TCA, the compound exhibits substantially greater NET selectivity than amitriptyline (NET Ki approximately 4 nM, SERT Ki approximately 18 nM) and reduced muscarinic antagonism (M1 Ki approximately 150 nM versus 18 nM for amitriptyline), producing a cleaner side effect profile. H1 antagonism remains significant (Ki approximately 10 nM) and contributes to residual sedation, but the anticholinergic burden is meaningfully lower. Plasma half-life is 18 to 35 hours; metabolism is via CYP2D6 (primary). Therapeutic plasma concentrations are well-defined (50 to 150 ng/mL) and routinely monitored, distinguishing nortriptyline from most modern antidepressants. Used as the canonical secondary amine TCA in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Desipramine

    Tricyclic antidepressant (secondary amine)

    The N-desmethyl active metabolite of imipramine; the most NET-selective TCA in clinical use.

    Abstract

    Desipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine; CAS 50-47-5; molecular formula C18H22N2; molecular weight 266.38) is the N-desmethyl active metabolite of imipramine, approved by the FDA in 1964 under the trade name Norpramin. The compound is the most NET-selective TCA in clinical use (NET Ki approximately 0.83 nM, SERT Ki approximately 17 nM, ratio approximately 20). Off-target activity is reduced compared to imipramine: muscarinic (M1 Ki approximately 200 nM), H1 (Ki approximately 60 nM), and alpha-1 (Ki approximately 100 nM) antagonism are all weaker than the parent compound, producing a cleaner profile though still TCA-like. Plasma half-life is 15 to 24 hours; metabolism is via CYP2D6 and CYP2E1. Sodium channel block and consequent cardiotoxicity in overdose remain limitations. Used as the canonical NET-selective TCA in mechanism studies and as a reference compound for noradrenergic pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.